Screener
Recursion Pharmaceuticals, Inc. RXRX Cost of Goods Sold
Cost of Goods Sold at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Grant revenue | 367 | 120 | 538 | 47 |
| Total revenue | 7,670 | 19,223 | 14,143 | 33,968 |
| Operating costs and expenses | ||||
| Cost of revenue | 11,491 | 20,161 | 23,981 | 41,990 |
| Research and development | 89,614 | 128,636 | 177,510 | 258,269 |
| General and administrative | 41,533 | 46,653 | 76,124 | 101,304 |
| Total operating costs and expenses | 142,638 | 195,450 | 277,615 | 401,563 |
| Loss from operations | (134,968) | (176,227) | (263,472) | (367,595) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s cost of goods sold?
- Recursion Pharmaceuticals, Inc. (RXRX) reported cost of goods sold of $11.49M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s cost of goods sold changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s cost of goods sold decreased by 43.0% year-over-year, from $20.16M to $11.49M.
- What does cost of goods sold mean?
- Cost Of Goods And Services Sold as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s cost of goods sold.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude